Holen Sie sich die Stockscreener-App
8.05
1.47%
-0.12
Handel nachbörslich:
7.83
-0.22
-2.73%
Schlusskurs vom Vortag:
$8.17
Offen:
$8.25
24-Stunden-Volumen:
2.12M
Relative Volume:
1.13
Marktkapitalisierung:
$1.40B
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-2.875
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
+23.66%
1M Leistung:
+17.35%
6M Leistung:
+176.63%
1J Leistung:
+65.64%
1-Tages-Spanne:
$7.81
$8.36
1-Wochen-Bereich:
$6.28
$8.36
52-Wochen-Spanne:
$1.775
$8.36
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
8.05 | 1.42B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics stock hits 52-week high at $7.65 - Investing.com
Should I hold or sell Relay Therapeutics Inc. stock in 2025CEO Change & AI Based Buy and Sell Signals - newser.com
Key metrics from Relay Therapeutics Inc.’s quarterly data2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Is Relay Therapeutics Inc. stock a top momentum playJuly 2025 Drop Watch & Daily Market Momentum Tracking - newser.com
Relay Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Price Swings & Capital Protection Trading Alerts - newser.com
Relay Therapeutics Inc. (RLAY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Commit To Buy Relay Therapeutics At $5, Earn 22.4% Annualized Using Options - Nasdaq
Citizens reiterates Market Outperform rating on Relay Therapeutics stock By Investing.com - Investing.com Canada
What analysts say about Relay Therapeutics Inc stockChart Pattern Recognition & Outstanding Growth Strategies - earlytimes.in
How Relay Therapeutics Inc. stock compares to growth peersTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Relay Therapeutics Inc. stock positioned for long term growth - newser.com
Does Relay Therapeutics Inc. show high probability of reboundProduct Launch & Reliable Price Action Trade Plans - newser.com
Backtesting results for Relay Therapeutics Inc. trading strategiesShare Buyback & Growth Focused Stock Reports - newser.com
Analyzing recovery setups for Relay Therapeutics Inc. investorsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Relay Therapeutics Q3 2025 Earnings Preview - MSN
Why Relay Therapeutics Inc. stock is trending among retail traders2025 Trading Recap & Free Community Supported Trade Ideas - Fundação Cultural do Pará
What machine learning models say about Relay Therapeutics Inc.2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Why retail investors favor Relay Therapeutics Inc. stockQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com
How to use a screener to detect Relay Therapeutics Inc. breakoutsShare Buyback & Safe Swing Trade Setups - newser.com
Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? - Yahoo Finance
Relay Therapeutics Inc Stock Analysis and ForecastTrend Following Strategies & Minimal Capital Growth Plans - earlytimes.in
Regression analysis insights on Relay Therapeutics Inc. performanceDollar Strength & AI Powered Market Entry Ideas - newser.com
Using Ichimoku Cloud for Relay Therapeutics Inc. technicalsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Why hedge funds are buying Relay Therapeutics Inc. stockMarket Volume Summary & Consistent Return Investment Signals - newser.com
Has Relay Therapeutics Inc. found a price floor2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Relay Therapeutics Trims Costs And Stays Well-Funded - Finimize
Full technical analysis of Relay Therapeutics Inc. stockMarket Rally & Safe Entry Trade Reports - newser.com
Wells Fargo Maintains Relay Therapeutics (RLAY) Equal-Weight Recommendation - Nasdaq
Relay Therapeutics (RLAY) Analyst Rating Update by Wells Fargo | RLAY Stock News - GuruFocus
Relay Therapeutics Reports Q3 2025 Financial Progress - TipRanks
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 - Investing News Network
Relay Therapeutics (RLAY) Advances Clinical Trials in Breast Can - GuruFocus
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates - Investing News Network
Relay Therapeutics Inc Reports Q3 2025 EPS of -$0.43, Revenue at $0, Missing Estimates - GuruFocus
Relay Therapeutics slightly misses Q3 net loss estimates, expects cash reserves to fund operations into 2029 - TradingView
Relay Therapeutics Appoints Two New Board Members - TradingView
[10-Q] Relay Therapeutics, Inc. Quarterly Earnings Report | RLAY SEC FilingForm 10-Q - Stock Titan
[8-K] Relay Therapeutics, Inc. Reports Material Event | RLAY SEC FilingForm 8-K - Stock Titan
RLAY: Clinical progress, reduced losses, and strong cash position support operations into 2029 - TradingView
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Oct 29 '25 |
Sale |
7.50 |
21,394 |
160,455 |
337,469 |
| Rahmer Peter | See remarks |
Oct 28 '25 |
Sale |
7.29 |
19,135 |
139,494 |
358,863 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 28 '25 |
Sale |
7.29 |
21,664 |
157,931 |
313,631 |
| Bergstrom Donald A | President, R&D |
Oct 28 '25 |
Sale |
7.29 |
30,897 |
225,239 |
521,823 |
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):